More on ACHL
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.78 |
|
|||
| Open | $0.77 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $0.81 | ||||
| Day Low | $0.76 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 119,428 | ||||
- Piper Sandler Downgrades Achilles Therapeutics (ACHL) to Neutral
- Form S-8 Achilles Therapeutics
- Form 20-F Achilles Therapeutics For: Dec 31
- Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
- Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
- Form SC 13G/A Achilles Therapeutics Filed by: Artal International S.C.A.
- Form SC 13G/A Achilles Therapeutics Filed by: BAKER BROS. ADVISORS LP
- Form SC 13G/A Achilles Therapeutics Filed by: Syncona Portfolio Ltd
- Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
- Form 144 Achilles Therapeutics Filed by: Peggs Karl Stuart Dr
Entities mentioned with ACHL
- Earnings | View Related Stories »
- IPO | View Related Stories »
- JPMorgan | View Related Stories »
- Definitive Agreement | View Related Stories »
- 13G | View Related Stories »
- Chardan Capital Markets | View Related Stories »
- H.C. Wainwright | View Related Stories »
- RA Capital | View Related Stories »
- Show More...
